• Aliases: Antibody IMC-3G3, IMC-3G3; LY3012207
    • A fully human IgG1 monoclonal antibody that selectively binds to PDGFR-α, blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in the inhibition of angiogenesis and tumor cell proliferation
    • FDA approved for treatment (in combination with doxorubicin) of adults with soft tissue STS with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery
    • Recommended dose: 15 mg/kg IV on cycles; after 8 cycles are completed, continue olaratumab as a single agent. Premedicate with diphenhydramine IV and dexamethasone 10 mg IV on cycle 1 day 1 of olaratumab
    Other topics in Targeted and Immunotherapy Agents